跳至主要内容
临床试验/2023-503424-12-00
2023-503424-12-00招募中4 期

Targeting branched-chain amino acid oxidation to improve glycaemic control in patients with type 2 diabetes

Maastricht University1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年7月13日最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
26
试验地点
1
主要终点
Glucose levels will be measured after an overnight fast expressed in mmol/l.

研究概览

简要总结

The primary objective is to investigate if prolonged boosting of BCAA oxidation will substantially lower fasting plasma glucose levels in patients with T2D.

研究设计

分配方式
Randomized
主要目的
Double-blind, Placebo-controlled, Cross-over Rct
盲法
Double (Investigator, Subject, Analyst)

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Patients are able to provide signed and dated written informed consent prior to any study specific procedures
  • No signs of active liver or kidney malfunction
  • Women are post-menopausal (defined as at least 1 year post cessation of menses) and aged ≥ 45 and ≤ 76 years. Males are aged ≥ 40 years and ≤ 76 years
  • Patients should have suitable veins for cannulation or repeated venipuncture
  • BMI: 25-38 kg/m2
  • Diagnosed with T2D at least 1.5 years before the start of the study
  • Relatively well-controlled T2D: HbA1c < 8.5%
  • Oral glucose lowering medication: metformin only or in combination with sulfonylurea agents and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months
  • No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy

排除标准

  • Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator
  • Participate in physical activity more than 3 times a week
  • Unstable body weight (weight gain or loss > 5 kg in the last three months)
  • Insulin dependent T2D
  • Patients with congestive heart failure and and/or severe renal and or liver insufficiency or known sodium retention with oedema
  • Patients using Probalan (probenecid), Haldol (haloperidol), Depakene (valproate) or medical products containing corticosteroids
  • Men: Hb <8.4 mmol/L, Women: Hb <7.8 mmol/l
  • Any contra-indication MRI scanning. These contra-indications include patients with e.g. the following: • Central nervous system aneurysm clip • Implanted neural stimulator • Implanted cardiac pacemaker of defibrillator • Cochlear implant • Metal containing corpora aliena in the eye or brains

结局指标

主要结局

Glucose levels will be measured after an overnight fast expressed in mmol/l.

Glucose levels will be measured after an overnight fast expressed in mmol/l.

次要结局

  • Glucose clearance in ml/kg determined during an OGTT at 6 weeks and glucose disposal rate (Rd) in mol/kg/min measured with the clamp at 12 weeks
  • O2-flux in pmol/mg/s measured with high resolution respirometry
  • insulin-stimulated change in respiratory exchange ratio (RER) with use of indirect calorimetry during the clamp
  • PCr/ATP-ratio determined with phosphorus magnetic resonance spectroscopy
  • Cardiac function will be measured in 2 ways: 1) ejection fraction (microL) with use of cine-MRI 2) diastolic cardiac function with use of ultrasound (transthoracic echocardiography) and will be assessed with the following parameters: • Left atrial maximum volume (ml) • Peak E-wave velocity (cm/sec) • Peak A-wave velocity (cm/sec) • Pulsed wave TDI e’velocity (cm/sec) at lateral and septal basal regions • Tricuspid regurgitation systolic jet velocity (m/sec)
  • Cognitive function will be assessed in 2 ways: 1) Use of CANTAB 2) Questionnaires (Beck’s Depression Inventory and Pittsburgh Sleep Quality Index)
  • Continuous glucose and ketone profile will be measure with use of the CGKM sensor

研究者

申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

Dr. Esther Phielix

Scientific

Maastricht University

研究点 (1)

Loading locations...

相似试验